Detalhe da pesquisa
1.
Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.
Pediatr Blood Cancer
; 70(5): e30271, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815392
2.
Experience with a Reduced Toxicity Allogeneic Transplant Regimen for Non-CGD Primary Immune Deficiencies Requiring Myeloablation.
J Clin Immunol
; 41(1): 89-98, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33067658
3.
Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia.
J Pediatr Hematol Oncol
; 43(4): 152-154, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32496443
4.
Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2).
J Allergy Clin Immunol
; 145(6): 1664-1672.e10, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31945408
5.
Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia.
Biol Blood Marrow Transplant
; 26(11): e280-e285, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32755637
6.
Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities.
Pediatr Blood Cancer
; 67(4): e28199, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32020723
7.
Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia.
Blood
; 138(21): 2138-2142, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34499715
8.
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.
Blood
; 128(19): 2350-2358, 2016 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27625357
9.
Allogeneic hematopoietic stem cell transplant outcomes for patients with dominant negative IKZF1/IKAROS mutations.
J Allergy Clin Immunol
; 144(1): 339-342, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30965037
10.
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns.
EClinicalMedicine
; 65: 102268, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37954907
11.
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
J Clin Oncol
; 41(2): 354-363, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108252
12.
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.
Blood Adv
; 7(12): 2758-2771, 2023 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36857419
13.
Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.
Blood Adv
; 7(14): 3725-3734, 2023 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37042921
14.
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
Blood Adv
; 6(7): 1961-1968, 2022 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34788386
15.
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report.
Blood Adv
; 6(2): 600-610, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794180
16.
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
J Clin Oncol
; 40(9): 945-955, 2022 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34882493
17.
Quality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact Outcomes.
Transplant Cell Ther
; 28(5): 233-241, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35151937
18.
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
Blood Adv
; 6(14): 4251-4255, 2022 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35580324
19.
High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy.
Blood Adv
; 4(4): 717-727, 2020 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32092141
20.
Is it time to consider early discharge for pediatric patients after hematopoietic stem cell transplant?
Pediatr Transplant
; 18(4): 325-6, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24802340